 Citybizlist |
Targacept: Drug missed goal due to analysis error
BusinessWeek Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent, … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept reports error in asthma study Targacept loses big shareholder, finds error in previous study |
View full post on asthma – Google News